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The Effect of Intravitreal Bevacizumab in Patients with Acute 
Central Serous Chorioretinopathy
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Department of Ophthalmology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea
Purpose: To evaluate the effect of intravitreal bevacizumab injection (IVBI) in acute central serous chorioretinopathy 
(CSC) patients.
Methods: Patients with acute CSC received IVBI (1.25 mg/0.05 mL) or observation by randomization. Twelve eyes 
in each group completed 6 months of regular follow-up and were ultimately included in this study. Each patient 
was assessed using best corrected visual acuity measurements, fluorescein angiography, and optical coherence 
tomography at baseline and had regular follow-ups after treatment.
Results: All patients showed improvements in visual acuity and fluorescein angiographic leakage and had reso-
lution of their neurosensory detachment following treatment. There were no significant differences in visual acui-
ty, central retinal thickness, or remission duration between the IVBI group and the control group at baseline or af-
ter treatment (p＞0.05).
Conclusions: Intravitreal bevacizumab showed no positive effect in acute CSC patients compared to the ob-
servation group, and there were no adverse effects of treatment. Further investigation will be helpful to under-
stand this therapy in patients with CSC.
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Central serous chorioretinopathy (CSC) is characterized 
by the development of serous neurosensory retinal detach-
ment at the posterior pole [1]. In the majority of patients, 
CSC is self-limited, and patients usually have a good visual 
prognosis. However, in some cases of CSC, patients develop 
progressive visual loss due to persistent serous retinal de-
tachment, cystoid macular degeneration, or retinal pigment 
epithelium decompensation [2,3].
Clinicians usually elect to observe patients with acute 
CSC, because these patients generally show self-remission, 
and traditional treatments like laser photocoagulation or pho-
todynamic therapy may induce complications [4,5]. However, 
patients with acute CSC often desire more expedient reso-
lution of their disease.
The pathophysiology of CSC remains poorly understood. 
The advent of indocyanine green angiography, however, has 
demonstrated choroidal involvement in the disease. It is like-
ly that choroidal hyperpermeability is an early event in the 
development of symptomatic CSC where, under the appro-
priate circumstances, it may lead to retinal pigment epithelial 
detachment followed by neurosensory detachment [5].
 
Vascular endothelial growth factor (VEGF) has been im-
plicated as the major factor responsible for increased vas-
cular permeability [6]. Recently, bevacizumab (Avastin; 
Genentech Inc., San Francisco, CA, USA), an antibody to 
VEGF, has been shown to have anti-permeability properties. 
Intravitreal injection of bevacizumab (IVBI) has been re-
ported to be associated with visual improvement and reduced 
neurosensory detachment without adverse events in patients 
with CSC [7]. In this study, we investigated the effect of 
IVBI in patients with acute CSC.
Materials and Methods
This was a prospective, randomized comparative study. 
Patients with symptomatic CSC of less than a 3-month dura-
tion were prospectively recruited between March 2008 and 
August 2008. The diagnosis of CSC was established by the 
presence of serous macular detachment on fundus examina-Korean J Ophthalmol Vol.24, No.3, 2010
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Table 1. Baseline characteristics of patients with acute central serous chorioretinopathy
Characteristics Observation 
(n=12)
Intravitreal bevacizumab 
(n=12)
p-value
Age (yr) 40.7±7.0 45.6±10.4 0.234
*
Gender (male:female) 11:1 9:3 0.217
†
Laterality (right:left)  8:4 5:7 0.272
†
Number of CSC episodes (first:second)  9:3 7:5 0.894
†
Duration of current CSC episode (wk)  5.4±1.6 5.8±1.5 0.789
*
Spherical equivalent refractive error (diopters) -0.50±1.2 -0.33±1.2 0.567
*
Baseline logMAR BCVA 0.20±0.21 0.23±0.21 0.721
*
Baseline central macular thickness (μm) 442±160 431±107 0.977
*
Values are presented as mean±SD unless otherwise indicate. SD=standard deviation; CSC=central serous chorioretinopathy; logMAR 
BCVA=logarithm of minimal angle of resolution best-corrected visual acuity. 
*Mann-Whitney U-test; 
†Fisher exact test. 
tion and dilated choroidal vasculature and hyperpermeability 
on indocyanine green angiography. Patients who had re-
ceived any previous treatment, including photodynamic ther-
apy or focal thermal laser photocoagulation for CSC, or who 
had evidence of choroidal neovascularization, polypoidal 
choriovasculopathy, or other maculopathy on clinical exami-
nation, fluorescein angiography, or indocyanine green an-
giography were excluded from the study. Informed consent 
was obtained from all subjects. The protocol was approved 
by the Institutional Review Board of the hospital. Patients 
were randomized into the IVBI group or the observation 
group at a ratio of 1:1. The randomization sequence was gen-
erated using a computerized randomization table.
Patients in the IVBI group received only a single intra-
vitreal injection of bevacizumab (1.25 mg in 0.05 mL) under 
standard protocol conditions. Eyes were injected less than 
one week after diagnosis in our clinic. The observation group 
was observed without any treatment or any medication. Each 
patient underwent clinical assessments, including best-cor-
rected visual acuity measurement in Snellen units, applana-
tion tonometry, fundus examination, fluorescein angiog-
raphy, indocyanine green angiography, and optical coher-
ence tomography (OCT) at baseline. Baseline central retinal 
characteristics were analyzed using OCT (Stratus III OCT 
ver. 4.0; Carl Zeiss Meditec, Dublin, CA, USA) with 6 diago-
nal, slow 6-mm radial line scans through a dilated pupil. The 
central 1-mm macular thickness (CMT) was obtained using 
the macular thickness map for our calculations.
Regarding follow-up, the patients were examined at 
4-week intervals with slit-lamp biomicroscopy and OCT, and 
fluorescein angiography was performed at the discretion of 
the examiner. No other treatment for CSC was performed 
during the study. The primary outcome of the study was the 
time measured from baseline to complete absorption of sub-
retinal fluid during follow-up. Secondary outcome measures 
included serial changes in the logarithm of the minimum an-
gle of resolution (logMAR) visual acuity and OCT CMT.
Statistical analyses were performed using a commercially 
available statistical software package (SPSS ver. 11.5; SPSS 
Inc., Chicago, IL, USA). Snellen units were converted to 
logMAR units for statistical analysis. Univariate categorical 
analyses were performed using the Mann-Whitney U-test or 
the Fisher exact test as appropriate. Data was analyzed via re-
peated-measures analysis of variance with Bonferroni 
correction. Statistical significance was set at 0.05 (2-sided) 
in all tests. 
Results
We collected data from 32 eyes during the study period. 
Four eyes were excluded due to irregular follow-up, and four 
eyes were excluded due to the lack of post-IVBI OCT data. 
Thus, 24 eyes with at least 6 months of follow-up were ulti-
mately included in this study. The mean age±SD of the pa-
tients was 43.2±9.0 years. There were 20 men and 4 women. 
The IVBI group included 12 patients (12 eyes), and the ob-
servation group included 12 patients (12 eyes). No ocular or 
systemic complications were detected during the follow-up 
period after IVBI. Demographic data on sex, age, laterality of 
the eyes, and symptom duration showed no significant differ-
ences between the 2 groups. The differences in baseline visu-
al acuity (logMAR) and baseline CMT between the 2  groups 
were not significant. The baseline characteristics of the 2 
groups are shown in Table 1. 
All patients in the 2 groups had complete resolution of 
their macular subretinal fluid during the 6 months of fol-
low-up. The mean remission periods from diagnosis were 
13.4±4.8 weeks in the observation group and 13.6±7.6 weeks 
in the IVBI group. There was no statistically significant dif-
ference between the 2 groups (p=0.783, Mann-Whitney 
U-test). 
After 6 months of follow-up, the mean±SD visual acuity of 
the IVBI group improved to 0.02±0.04, whereas that of the 
observation group improved to 0.02±0.05. The difference be-
tween the 2 groups was not statistically significant (p=0.287, 
Mann-Whitney U-test). The mean logMAR visual acuity of 
the 2 groups showed no difference at any follow-up visit. 
After 6 months of follow-up, the means±SD CMT for the JW Lim, et al. Intravitreal Bevacizumab in Central Serous Chorioretinopathy
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Fig.1. (A) Graph showing serial changes in the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR 
BCVA) for patients in the intravitreal bevacizumab injection (IVBI) group (solid line) and in the observation group (dashed line). Error bars 
represent standard errors of the mean. (B) Graph showing the serial changes in mean central macular thicknesses as measured using optical co-
herence tomography in the IVBI group (solid line) and in the observation group (dashed line). Error bars represent standard errors of the mean.
IVBI group and the control group were 207±50 μm and 
187±31 μm, respectively (p=0.377, Mann-Whitney U-test). 
The mean CMTs of the 2 groups showed no difference at any 
visit during the follow-up period. The serial changes in visual 
acuity and CMT are shown in Fig. 1. 
Discussion
Typical acute CSC is characterized by duration of symp-
toms and/or retinal detachment of less than 6 months and 
monofocal or paucifocal fluorescein angiographic retinal 
pigment epithelium leakage [5,8].The treatment of CSC is 
based largely on observation. The high spontaneous remission 
rate favors conservative management, lifestyle counseling, 
and discontinuation of glucocorticoid medication as first-line 
therapeutic options. Such a strategy can be expected to be 
followed by a resolution of detachment in nearly 90% of cases 
within 1.5 months [9,10]. If detachment persists for greater 
than 6 months, photocoagulation or photodynamic therapy 
should be considered. Although in most cases visual acuity 
returns to 20/25 or better, patients often desire earlier recovery 
of visual acuity and faster disease remission. Photocoagulation 
may induce scotoma formation in the central visual field 
through retinal pigment epithelium damage at the macula, 
and photodynamic therapy necessitates the avoidance of 
physical activity after treatment and is associated with high 
cost in South Korea. The relatively good visual acuity of 
CSC patients and clinician concern about the possibility of 
complications gives cause to avoid treatment in the acute 
period. However, intravitreal injection can be conducted in 
the office and does not necessitate limitation of activity. 
Rarely, intravitreal injection is associated with complications 
like endophthalmitis or intraocular inflammation. We con-
sider intravitreal injection to be a new treatment option in 
acute CSC patients and an alternative to observation or an-
other treatment. 
Vascular endothelial growth factor has profound effects 
on vascular permeability. Bevacizumab is a full-length anti-
body that binds all isoforms of VEGF. A growing number of 
reports in the literature support its safety and efficacy in 
many disorders [11-14]. However, the direct role of VEGF 
in CSC remains unknown. Indocyanine green angiography 
in patients with CSC has demonstrated evidence of choroi-
dal lobular ischemia, choroidal venous congestion, and mul-
tiple areas of choroidal vascular hyperpermeability [15,16]. 
Choroidal ischemia in CSC may induce an increase in the 
concentration of VEGF. Thus, bevacizumab may theoretically 
reduce choroidal hyperpermeability in CSC. Although there 
have been no reports measuring VEGF levels in CSC, there 
are 2 reports of treatment with IVBI in patients with acute 
CSC.
 Torres-Soriano et al. [7] reported the use of IVBI in 5 
eyes and found that the procedure was associated with visual 
improvement without adverse events. Seong et al. [17] also 
reported that 10 eyes showed resolution of neurosensory de-
tachment within 1 month after IVBI. That study, however, 
was a small case series and had no control group. 
Our results demonstrate that, in patients with acute CSC, 
IVBI showed no positive or negative effect in terms of earlier 
remission, functional results, or anatomical results. No ad-
verse events were found to be associated with the treatment. 
Limitations of this study include the small number of patients 
and the short follow-up period. Also, there are various forms 
of CSC, and only acute CSC was investigated in this study. 
We did not investigate recurrence or long-term effects. 
Furthermore, there is no data available to support or refute 
the proposed mechanism of IVBI in CSC. Further inves-Korean J Ophthalmol Vol.24, No.3, 2010
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tigation will be helpful for understanding this therapy in pa-
tients with CSC.
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